## Edgar Filing: Jooss Karin - Form 4

Jooss Karin										
Form 4	0									
March 18, 201									PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287		
Check this if no longer subject to Section 16. Form 4 or Form 5 obligations may contin <i>See</i> Instruct 1(b).	Filed pur Gection 17(	<b>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							January 31, 2005 average urs per . 0.5	
(Print or Type Re	sponses)									
Jooss Karin S F			2. Issuer Name <b>and</b> Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	HERAPEUTIC ENERAL ATC			of Earliest Tr Day/Year) 2019	ransaction		X Director Officer (giv below)		% Owner ler (specify	
Filed(M				Amendment, Date Original d(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting</li> </ul>			
SAN DIEGO,	, CA 92121						Person	whole than one R	epotting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, i any (Month/Day/Year)		Date, if	Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or		Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Reminder: Repor	t on a separate line	e for each cla	ass of sec			(D) Price	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Jooss Karin - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Transaction Date 3A. Deemed Ionth/Day/Year) Execution Date, if any (Month/Day/Year)		TransactionDerivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 18.21	03/14/2019		А	24,000	<u>(1)</u>	03/14/2029	Common Stock	24,000	

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
	D	Director	10% Owner	Officer	Other		
looss Karin C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUI SAN DIEGO, CA 92121	TE 200	X					
Signatures							
/s/ Cindy R. Tahl, as Attorney-in-Fact	03/18/2019	)					

Date

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning on April 14, 2019 such that this option is fully exercisable on March 14, 2022.
- (2) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

8 E S ()